![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, April 14, 2021 10:52:39 AM
Published: Apr 13, 2021 By Gail Dutton
Stem Cells
On Tuesday, Celularity received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its off-the-shelf natural killer cell therapy for malignant gliomas.
The news coincided with the American Association for Cancer Research (AACR) Annual Meeting 2021, where Celularity delivered an oral presentation and two posters. Each showcased the viability of that therapeutic compound, CYNK-001, as a treatment for multiple, disparate indications.
The presentations focused on CYNK-001 as an off-the-shelf therapeutic for both COVID-19 and for glioblastoma, but this non-genetically modified cryopreserved human placental hematopoietic stem cell-derived natural killer (NK) cell therapy also is being developed for leukemia. It is in Phase I trials for glioblastoma multiform (GBM), and was granted Fast Track designation by the FDA last month.
CYNK-001 is based on an earlier candidate, PNK-007, currently in trials for multiple myeloma and acute myeloid leukemia (AML). The difference between the two, Robert J. Hariri, M.D., Ph.D., founder, chair and CEO of Celularity, explained, is that “CYNK-001 is validated and cryopreserved.” Therefore, it may be an off-the-shelf allogeneic therapy with a long shelf-life.
The COVID-19 trial was the first time CYNK-001 was used for a non-cancer indication. The trial measured safety and efficacy. Results showed the infusions “generally were well-tolerated and three of four patients experienced improvements in oxygenation, inflammatory markers and radiographic findings,” according to the abstract.
In gastric cancer, the overexpression of human epidermal growth factor receptor 2 (HER2) has been reported in about 20% of all cases and is linked to poor outcomes. Another compound, CYNK-101, showed synergistic anti-tumor antibody dependent cellular cytotoxicity when administered with Trastuzumab in vitro, ex vivo and in vivo.
Notably, “It is exactly the same candidate in each of those programs,” Hariri told BioSpace.
That one therapy has such diverse applications is possible because of its origin: placental stem cells.
“The biology of the placenta is remarkable,” Hariri said. “It’s nature’s stem cell factory. We originally thought it was merely a vascular interface between the baby and mother, but it’s actually a life-support system to create an environment for the proliferation and differentiation of stem cells that derive from the primordial stem cell created at fertilization.”
Specifically, “The placenta produces natural killer (NK) cells that are part of the innate immune system,” defending fetuses from infectious diseases and cancer. “One in one thousand women have cancer during pregnancy, yet the incidence of transfer is essentially non-existent,” he pointed out.
That’s because of the NK cells that, likewise, protect the baby from viral infections.
“Placental NK cells recognize stress antigen found on infected cells,” Hariri continued. “Adult-derived NK cells don’t express the same array or recognition markers found on placental cells, therefore, the youth of placental cells is important,” because of their unique characteristics.
“Stemness” is one example, he said. “Stemness is a characteristic of stem cells that is associated with their very versatile differentiality. They can access the entire genome of the stem cell to synthesize all the products the stem cell encodes for.” They also have “better proliferative performance, greater persistence and are immunologically naïve, so they haven’t yet developed the self-expression that lets them be targeted by a recipient’s immune system.
“Therefore, therapies derived from placental stem cells may be safer and more potent than those derived from ‘foreign’ cells.” Because the immune system doesn’t see these cells a ‘foreign,’ patients can be retreated as necessary “until you get the response you want.”
Placental stem cells can solve one of the challenges stem cell therapies face: access to raw material. Each post-partum placenta can produce hundreds to thousands of doses, making this a scalable, economic source of high-quality stem cells.
As Celularity looks to the future, “We are very cognizant of being thoughtful regarding the clinical indications we select. This is a very competitive landscape.”
It plans to produce its products inhouse and aims to be a world leader in the manufacture of cellular medicine.
“The key is consistency and reliability” Hariri said.
Because Celularity spun out from Celgene in 2017, its team has years of experience engineering and manufacturing NK cells and other cell types.
“Our headquarters houses GMP manufacturing capabilities with 15 independent production suites, so we can produce a range of products in parallel under rigorous regulatory guidelines,” he said.
"The refusal of the real is the number one dogma of our time" Rene Girard
Recent SRNE News
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 09:31:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 08:15:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/13/2023 01:51:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2023 09:25:07 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/07/2023 08:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2023 10:01:54 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM